Search

Displaying results 771 - 780 of 10000 in total
  1. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    [L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. … [L41860] It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.[A248775]

  2. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  3. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.

    Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  4. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    ), another tyrosine kinase inhibitor used as a first-line treatment for CML. … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec

  5. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.

  6. Drug

    Ritonavir

    go.drugbank.com/drugs/DB00503
    ApprovedInvestigational

    American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for … Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV.

    Mixtures: LOPIMUNE ® + RITONAVIR 10 MG - PELLETS EN CÁPSULAS ORALES, LOPINAVIR E RITONAVIR MYLANCategories: Antivirals used in combination for the treatment of HIV infections
  7. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.

    Products: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN)
  8. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    +7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) Score were observed. … Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.

  9. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. … In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    combination in the form of levodopa and carbidopa. … When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the